Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 20/20 | 0.62 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.59 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.59 |
| ▸ | EML4 | Q9HC35 | 1/20 | 0.59 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30617218 | 1.00 | EGFR (0.62) | EGFRPTK2KCNH2EML4ALK | |
| SCHEMBL21232044 | 0.92 | EGFR (0.62) | EGFREML4ALK | |
| SCHEMBL30617198 | 0.91 | EGFR (0.62) | EGFREML4ALK | |
| SCHEMBL21232446 | 0.91 | EGFR (0.62) | EGFREML4ALK | |
| SCHEMBL22494980 | 0.89 | EGFR (0.61) | EGFRPTK2KCNH2EML4ALK | |
| SCHEMBL30617211 | 0.89 | EGFR (0.61) | EGFRPTK2KCNH2EML4ALK | |
| SCHEMBL26325472 | 0.89 | EGFR (0.60) | EGFRPTK2KCNH2EML4ALK | |
| SCHEMBL30775468 | 0.88 | EGFR (0.59) | EGFRPTK2EML4ALK | |
| SCHEMBL21231997 | 0.88 | EGFR (0.71) | EGFRKCNH2EML4ALK | |
| SCHEMBL22494978 | 0.88 | EGFR (0.59) | EGFRPTK2EML4ALK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250057850-A1 | ERBB/BTK INHIBITORS | DIZAL JIANGSU PHARMACEUTICAL CO LTD (CN) | 2025-02-20 | — | — | US | disclosed |
| EP-4356975-A2 | ERBB/BTK INHIBITORS | DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) | 2024-04-24 | — | — | EP | disclosed |
| EP-3746424-B1 | ERBB/BTK INHIBITORS | DIZAL JIANGSU PHARMACEUTICAL CO LTD (CN) | 2024-03-06 | — | — | EP | disclosed |
| US-11896597-B2 | ErbB/BTK inhibitors | DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) | 2024-02-13 | — | — | US | disclosed |
| US-20230293535-A1 | ERBB/BTK INHIBITORS | DIZAL JIANGSU PHARMACEUTICAL CO LTD (CN) | 2023-09-21 | — | — | US | disclosed |
| US-20230293535-A1 | ERBB/BTK INHIBITORS | DIZAL JIANGSU PHARMACEUTICAL CO LTD (CN) | 2023-09-21 | — | — | US | disclosed |
| US-11504375-B2 | ErbB/BTK inhibitors | DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) | 2022-11-22 | — | — | US | disclosed |
| US-20210252005-A1 | ERBB/BTK INHIBITORS | DIZAL (SHANGHAI) PHARMACEUTICAL CO., LTD. (CN) | 2021-08-19 | — | — | US | disclosed |
| US-20210252005-A1 | ERBB/BTK INHIBITORS | DIZAL (SHANGHAI) PHARMACEUTICAL CO., LTD. (CN) | 2021-08-19 | — | — | US | disclosed |
| US-11007198-B2 | ErbB/BTK inhibitors | DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) | 2021-05-18 | — | — | US | disclosed |
| US-11007198-B2 | ErbB/BTK inhibitors | DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) | 2021-05-18 | — | — | US | disclosed |
| EP-3746424-A1 | ERBB/BTK INHIBITORS | DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD (CN) | 2020-12-09 | — | — | EP | disclosed |
| US-20200316079-A1 | ERBB/BTK INHIBITORS | DIZAL (SHANGHAI) PHARMACEUTICAL CO., LTD. (CN) | 2020-10-08 | — | — | US | disclosed |
| US-20200316079-A1 | ERBB/BTK INHIBITORS | DIZAL (SHANGHAI) PHARMACEUTICAL CO., LTD. (CN) | 2020-10-08 | — | — | US | disclosed |
| WO-2019149164-A1 | ERBB/BTK INHIBITORS | DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD (CN) | 2019-08-08 | — | — | WO | disclosed |
| WO-2019149164-A1 | ERBB/BTK INHIBITORS | DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD (CN) | 2019-08-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11896597-B2 | ErbB/BTK inhibitors | ERBB2, BTK, ERBB3 | EGFR 5/4885PTK2 88/4885KCNH2 3793/4885 |
| US-20210252005-A1 | ERBB/BTK INHIBITORS | ERBB2, BTK, ERBB3 | EGFR 5/4885PTK2 88/4885KCNH2 3793/4885 |
| US-11007198-B2 | ErbB/BTK inhibitors | ERBB2, BTK, ERBB3 | EGFR 5/4885PTK2 88/4885KCNH2 3793/4885 |
| US-20200316079-A1 | ERBB/BTK INHIBITORS | ERBB2, BTK, ERBB3 | EGFR 5/4885PTK2 88/4885KCNH2 3793/4885 |
| US-11504375-B2 | ErbB/BTK inhibitors | ERBB2, BTK, ERBB3 | EGFR 5/4885PTK2 88/4885KCNH2 3793/4885 |
| US-20230293535-A1 | ERBB/BTK INHIBITORS | ERBB2, BTK, ERBB3 | EGFR 5/4885PTK2 88/4885KCNH2 3793/4885 |
| US-20250057850-A1 | ERBB/BTK INHIBITORS | ERBB2, BTK, ERBB3 | EGFR 5/4885PTK2 88/4885KCNH2 3793/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.